Title: A Phase 2 Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Principal Investigator: Dr. Pinkal Desai
Contact: Tania Curcio, RN
Phone: (212) 746-746-2571
Sponsor: Weill Cornell Medicine

This clinical study is aimed at men and women with a diagnosis of: Chronic Neutrophilic Leukemia (CNL), Chronic Myelomonocytic Leuekmia (CMML), atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and Myelodysplastic/Myeloproliferative Neoplasm Unclassifiable (MDS/MPN-U).

SGI-110 has demonstrated safety and efficacy in patients with MDS, Acute Myeloid Leukemia (AML), and CMML. Based on this data, it is believed that SGI-110 will result in similar affects in this patient set.

The study drug works by controlling gene expression and is hypothesized to safer than alternatives.

Duration of treatment is dependent on individual response and no experience of unacceptable side affects. Patients will be in follow-up monthly for six months

SGI-110 is administered subcutaneously on the first 5 days of every month

Key eligibility

  • Men and women age 18 and older
  • Diagnosis of CNL, CML, aCML, CMML, or MDS/MPN-unclassifiable
  • Patient has not had any chemotherapy (hydroxyurea excluded) or radiotherapy within 2 weeks prior to study entry
  • Detailed eligibility reviewed when you contact the study team

Disease Status: Myeloproliferative Neoplasms
Study Status:
IRB #:
Expiration: December 1, 2016